Lexaria Bioscience Corp Warrant 2020-12.01.26 on Lexaria Bioscience LEXXW 深 沪
等待开盘 04-03 09:30:00 美东时间
0.0012
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0012
- 总市值 6125.16
- 52周最高 0.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.0009
- 委 比 0.00%
- 总股本 510.43万
- 历史最高 5.19
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.0009
- 每 手 1
- 风险率 0.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Profusa (NASDAQ:PFSA) stock rose 48.6% to $0.86 during Thursday's regu...
今天 01:05
Lexaria Bioscience Receives 5 New Patents Including 2 For Diabetes Treatment Utilizing GLP-1 Drugs
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this update on additional new intellectual property ("IP") granted to the Company
03-26 21:24
Lexaria Bioscience Launches 2026 R&D Program With Human And Animal GLP-1 Studies To Expand Drug Delivery IP And Business Opportunities
Exciting new human and animal studies designed to enhance business opportunitiesKELOWNA, BC / ACCESS Newswire / March 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in
03-04 22:28
Lexaria Bioscience Results From Human Pilot Study, Comparing DehydraTECH-liraglutide Capsules To Injected Saxenda Branded Liraglutide, Achieves 22.7% Reduction In Adverse Events With DHT-LIR As Compared To SAX-LIR
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce final results from Human Pilot Study #5 (GLP-1-H25-5) (the "Study"), which
02-05 22:20
Lexaria Bioscience Shareholders Endorse Directors and Auditors
Lexaria Bioscience ( ($LEXX) ) just unveiled an announcement. At its annual sha...
01-29 03:17
Lexaria Deepens GLP-1 Focus With DehydraTECH Advances, Patents and Fresh Capital
Lexaria Bioscience ( ($LEXX) ) has provided an update. Lexaria’s CEO reported t...
01-13 00:07
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5
HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $4 to $1.5.
2025-12-26 19:06
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Lexaria Bioscience (NASDAQ:LEXX) stock increased by 6.5% to $0.89 durin...
2025-12-17 05:05
Lexaria Bioscience plummets on $3.5M equity offering
Lexaria Bioscience (LEXX) announced a registered direct offering to sell about 2.66 million shares at $1.315 per share, raising gross proceeds of roughly $3.5 million. The company will also issue unre...
2025-12-15 21:59
UPDATE: Lexaria Bioscience Announces $3.5M Registered Direct Offering Of 2,661,600 Shares At A Price Of $1.315/Share
Lexaria Bioscience Corp. (NASDAQ:LEXX)(LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of an
2025-12-15 21:51
